alexa A Randomized, Double-blind, Placebo-controlled Clinical Evaluation Of An Oral Supplement (Cold-EEZE® Zinc Gluconate Glycine Lozenge) Administered Daily As A Prophylactic For The Common Cold
ISSN: 2375-4273

Health Care : Current Reviews
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

6th Global Healthcare, Nutritionists & Dietician Annual Conference
December 05-07, 2016 Philadelphia, USA

Stephen Schwartz
International Research Services, Inc. Port Chester NY USA
ScientificTracks Abstracts: Health Care: Current Reviews
DOI: 10.4172/2375-4273.C1.032
Abstract
Statement of the Problem: The common cold occurs in varying severity and results in 75 million physician visits in the Unites States alone each year, with an incidence of over one billion. Evidence suggests that zinc ions help promote the production of adhesion molecules which block surface receptors located in the upper respiratory tract and thereby interrupt human rhinovirus HRV infection. Although recommendations for therapeutic options using zinc gluconate have remained limited to treating cold symptoms, prophylactic measures to limit and /or delay symptomology have not been thoroughly studied. Methodology & Theoretical Orientation: This was a 90-day, placebo-controlled, randomized, double-blind clinical evaluation of an oral supplement (Cold-EEZE® Zinc Gluconate Glycine Lozenge) in a panel of approximately 90 females and males. Test products were taken for 90 days. Assessments included symptom and resource utilization tracking and subjective questionnaires. Findings: Significantly fewer subjects who received daily Cold EEZE therapy exhibited multiple colds during the course of the study (8.3%) compared to those receiving daily placebo (product B), (36.3%, p=0.0321). Additionally these subjects showed fewer symptoms and less severe symptoms per cold event than those receiving placebo product (p<0.001). The average cold duration was also significantly less in the active product compared to placebo (p=0.019). The overall incidence of the development of any cold was not different between groups. Kaplan-Meier analysis was performed to determine if the use of Cold EEZE therapy delayed the onset of the first cold of the season. Data indicate that those treated with the active Cold- EEZE product had a mean survival time (i.e. time to first cold symptoms) of 73.51 days with standard error (SE) of 3.02 days while those treated with placebo had a mean survival time, days to first cold, of 52.09 days with a standard error of 5.96. This difference was shown to be significant at the p=0.041 level. Conclusion & Significance: Consuming two Cold-EEZE Zinc Gluconate Glycine lozenges, daily during the cold season, was effective in significantly delaying the onset of the common cold. Furthermore, when a cold did develop, the duration and severity of symptoms were reduced significantly.
Biography

Stephen Schwartz has his expertise in evaluation and support of consumer products. He has built a laboratory after years of experience in research, evaluation, both dermo-cosmetics and nutritional supplements.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords